K.J. Harrison & Partners Inc Takes $1.59 Million Position in Becton, Dickinson and Company $BDX

K.J. Harrison & Partners Inc bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,500 shares of the medical instruments supplier’s stock, valued at approximately $1,589,000.

A number of other hedge funds have also added to or reduced their stakes in BDX. Grandfield & Dodd LLC acquired a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $293,000. BlackRock Inc. bought a new position in Becton, Dickinson and Company during the second quarter worth $3,721,533,000. Pallas Capital Advisors LLC acquired a new stake in Becton, Dickinson and Company in the second quarter worth $920,000. Deutsche Bank AG bought a new stake in Becton, Dickinson and Company in the second quarter valued at $204,226,000. Finally, Perigon Wealth Management LLC acquired a new position in shares of Becton, Dickinson and Company during the second quarter valued at about $272,000. 86.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 11,779 shares of company stock worth $1,974,669. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.6%

BDX opened at $182.39 on Tuesday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The firm has a market capitalization of $50.26 billion, a PE ratio of 54.94, a P/E/G ratio of 12.93 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The company’s 50-day moving average is $158.48 and its 200 day moving average is $161.26.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Wall Street Analyst Weigh In

BDX has been the subject of several research reports. Bank of America reduced their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. The Goldman Sachs Group reduced their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday. Finally, Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.